MabThera maintenance therapy reduces the risk of death by almost half (48%) for patients with this form of NHL, compared to standard disease management.

• 与标准的疾病控制相比，美罗华维持疗法可使这类非霍奇金氏淋巴瘤患者的死亡风险率降低近一半（48%25）。